129 related articles for article (PubMed ID: 17036375)
1. Relevance of Ras gene mutations in the context of the molecular heterogeneity of multiple myeloma.
Intini D; Agnelli L; Ciceri G; Ronchetti D; Fabris S; Nobili L; Lambertenghi-Deliliers G; Lombardi L; Neri A
Hematol Oncol; 2007 Mar; 25(1):6-10. PubMed ID: 17036375
[TBL] [Abstract][Full Text] [Related]
2. Frequency and distribution of trisomy 11 in multiple myeloma patients: relation with overexpression of CCND1 and t(11;14).
Guglielmelli T; Giugliano E; Cappia S; Papotti M; Saglio G
Cancer Genet Cytogenet; 2007 Feb; 173(1):51-6. PubMed ID: 17284370
[TBL] [Abstract][Full Text] [Related]
3. Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations.
Agnelli L; Bicciato S; Mattioli M; Fabris S; Intini D; Verdelli D; Baldini L; Morabito F; Callea V; Lombardi L; Neri A
J Clin Oncol; 2005 Oct; 23(29):7296-306. PubMed ID: 16129847
[TBL] [Abstract][Full Text] [Related]
4. Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6.
Billadeau D; Liu P; Jelinek D; Shah N; LeBien TW; Van Ness B
Cancer Res; 1997 Jun; 57(11):2268-75. PubMed ID: 9187131
[TBL] [Abstract][Full Text] [Related]
5. Functional regulation of D-type cyclins by insulin-like growth factor-I and serum in multiple myeloma cells.
Glassford J; Rabin N; Lam EW; Yong KL
Br J Haematol; 2007 Oct; 139(2):243-54. PubMed ID: 17897300
[TBL] [Abstract][Full Text] [Related]
6. Cytogenetics and molecular cytogenetics in multiple myeloma.
Liebisch P; Döhner H
Eur J Cancer; 2006 Jul; 42(11):1520-9. PubMed ID: 16781866
[TBL] [Abstract][Full Text] [Related]
7. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis.
Bezieau S; Devilder MC; Avet-Loiseau H; Mellerin MP; Puthier D; Pennarun E; Rapp MJ; Harousseau JL; Moisan JP; Bataille R
Hum Mutat; 2001 Sep; 18(3):212-24. PubMed ID: 11524732
[TBL] [Abstract][Full Text] [Related]
8. RAS gene mutations in multiple myeloma and related monoclonal gammopathies.
Matozaki S; Nakagawa T; Nakao Y; Fujita T
Kobe J Med Sci; 1991 Feb; 37(1):35-45. PubMed ID: 1921261
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma.
Mattioli M; Agnelli L; Fabris S; Baldini L; Morabito F; Bicciato S; Verdelli D; Intini D; Nobili L; Cro L; Pruneri G; Callea V; Stelitano C; Maiolo AT; Lombardi L; Neri A
Oncogene; 2005 Apr; 24(15):2461-73. PubMed ID: 15735737
[TBL] [Abstract][Full Text] [Related]
10. Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease.
Lombardi L; Poretti G; Mattioli M; Fabris S; Agnelli L; Bicciato S; Kwee I; Rinaldi A; Ronchetti D; Verdelli D; Lambertenghi-Deliliers G; Bertoni F; Neri A
Genes Chromosomes Cancer; 2007 Mar; 46(3):226-38. PubMed ID: 17171682
[TBL] [Abstract][Full Text] [Related]
11. Genetic abnormalities and patterns of antigenic expression in multiple myeloma.
Mateo G; Castellanos M; Rasillo A; Gutiérrez NC; Montalbán MA; Martín ML; Hernández JM; López-Berges MC; Montejano L; Bladé J; Mateos MV; Sureda A; de la Rubia J; Díaz-Mediavilla J; Pandiella A; Lahuerta JJ; Orfao A; San Miguel JF
Clin Cancer Res; 2005 May; 11(10):3661-7. PubMed ID: 15897562
[TBL] [Abstract][Full Text] [Related]
12. Oncogenes in multiple myeloma: point mutation of N-ras.
Paquette RL; Berenson J; Lichtenstein A; McCormick F; Koeffler HP
Oncogene; 1990 Nov; 5(11):1659-63. PubMed ID: 2267133
[TBL] [Abstract][Full Text] [Related]
13. RAS mutations are uncommon in multiple myeloma and other monoclonal gammopathies.
Martín P; Santón A; García-Cosío M; Bellas C
Int J Oncol; 2005 Oct; 27(4):1023-8. PubMed ID: 16142319
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma.
Agnelli L; Fabris S; Bicciato S; Basso D; Baldini L; Morabito F; Verdelli D; Todoerti K; Lambertenghi-Deliliers G; Lombardi L; Neri A
Br J Haematol; 2007 Feb; 136(4):565-73. PubMed ID: 17367409
[TBL] [Abstract][Full Text] [Related]
15. [Molecular genetic methods for the prognostic criteria in multiple myeloma].
Mikala G; Jákó J; Vályi-Nagy I
Orv Hetil; 2005 Aug; 146(32):1673-82. PubMed ID: 16149245
[TBL] [Abstract][Full Text] [Related]
16. A potential role for centrosomal deregulation within IgH translocation-positive myeloma.
Maxwell CA; Pilarski LM
Med Hypotheses; 2005; 65(5):915-21. PubMed ID: 16023302
[TBL] [Abstract][Full Text] [Related]
17. Molecular pathogenesis and a consequent classification of multiple myeloma.
Bergsagel PL; Kuehl WM
J Clin Oncol; 2005 Sep; 23(26):6333-8. PubMed ID: 16155016
[TBL] [Abstract][Full Text] [Related]
18. Cellular and molecular genetic features of myeloma and related disorders.
Durie BG
Hematol Oncol Clin North Am; 1992 Apr; 6(2):463-77. PubMed ID: 1582985
[TBL] [Abstract][Full Text] [Related]
19. Genetics of multiple myeloma.
Higgins MJ; Fonseca R
Best Pract Res Clin Haematol; 2005; 18(4):525-36. PubMed ID: 16026735
[TBL] [Abstract][Full Text] [Related]
20. High-degree tumor budding and podia-formation in sporadic colorectal carcinomas with K-ras gene mutations.
Prall F; Ostwald C
Hum Pathol; 2007 Nov; 38(11):1696-702. PubMed ID: 17707462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]